Details on types of events and censoring in RFS analyses
| . | Insurance status . | COI . | ||
|---|---|---|---|---|
| Commercial (n = 124), n (%) . | Medicaid (n = 68), n (%) . | High COI (n = 143), n (%) . | Low COI (n = 45), n (%) . | |
| Events | ||||
| Relapse CD 19+ | 18 (14.52) | 11 (16.18) | 18 (12.59) | 11 (24.44) |
| Relapse CD 19- or lineage switch | 28 (22.58) | 14 (20.59) | 29 (20.28) | 8 (17.77) |
| Death without relapse | 1 (0.81) | 1 (1.47) | 0 (0) | 2 (1.40) |
| Censoring | ||||
| HSCT | 16 (12.90) | 6 (8.82) | 18 (12.59) | 4 (8.89) |
| Alternative cancer-therapy∗ | 16 (12.90) | 5 (7.35) | 17 (11.89) | 3 (6.67) |
| Subsequent malignancy | 2 (1.61) | 0 (0) | 0 (0) | 2 (4.44) |
| Last contact | 43 (34.68) | 31 (45.59) | 59 (41.26) | 15 (33.33) |
| . | Insurance status . | COI . | ||
|---|---|---|---|---|
| Commercial (n = 124), n (%) . | Medicaid (n = 68), n (%) . | High COI (n = 143), n (%) . | Low COI (n = 45), n (%) . | |
| Events | ||||
| Relapse CD 19+ | 18 (14.52) | 11 (16.18) | 18 (12.59) | 11 (24.44) |
| Relapse CD 19- or lineage switch | 28 (22.58) | 14 (20.59) | 29 (20.28) | 8 (17.77) |
| Death without relapse | 1 (0.81) | 1 (1.47) | 0 (0) | 2 (1.40) |
| Censoring | ||||
| HSCT | 16 (12.90) | 6 (8.82) | 18 (12.59) | 4 (8.89) |
| Alternative cancer-therapy∗ | 16 (12.90) | 5 (7.35) | 17 (11.89) | 3 (6.67) |
| Subsequent malignancy | 2 (1.61) | 0 (0) | 0 (0) | 2 (4.44) |
| Last contact | 43 (34.68) | 31 (45.59) | 59 (41.26) | 15 (33.33) |
HSCT, chemotherapy, other immunotherapy or CAR T-cell therapy, tyrosine kinase inhibitors.